Market Place
Sourcing Support
FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
Top 100 pharma & biotech deals in 2022
The pandemic years haven’t been great for dealmaking. Our analysis of top 10 biopharma M&A tra
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
